Search

Your search keyword '"Malak, Sandra"' showing total 172 results

Search Constraints

Start Over You searched for: Author "Malak, Sandra" Remove constraint Author: "Malak, Sandra"
172 results on '"Malak, Sandra"'

Search Results

1. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from EPICOVIDEHA survey

2. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

4. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings

5. International validation of a health-related quality-of-life questionnaire for Hodgkin lymphoma: the EORTC QLQ-HL27

6. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

7. Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study

9. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

10. Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML

11. Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study

12. Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers

13. International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high-and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia

16. P1683: THE EORTC QLQ-HL27: EORTC PROSPECTIVE INTERNATIONAL VALIDATION OF A DISEASE-SPECIFIC QUESTIONNAIRE FOR ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HODGKIN LYMPHOMA

17. International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia

18. The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients

19. International validation of two EORTC questionnaires for assessment of health‐related quality of life for patients with high‐grade non‐Hodgkin lymphoma (QLQ‐NHL‐HG29) and low‐grade non‐Hodgkin lymphoma (QLQ‐NHL‐LG20)

20. International validation of a health-related quality-of-life questionnaire for Hodgkin lymphoma: the EORTC QLQ-HL27

21. International validation of two EORTC questionnaires for assessment of health‐related quality of life for patients with high‐grade non‐Hodgkin lymphoma (QLQ‐NHL‐HG29) and low‐grade non‐Hodgkin lymphoma (QLQ‐NHL‐LG20)

22. COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA

24. International validation of the questionnaire for assessment of health‐related quality of life for patients with chronic lymphocytic leukaemia

25. International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemia

26. COVID-19 in vaccinated adult patients with hematological malignancies:preliminary results from EPICOVIDEHA

28. Correction to: Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study

29. Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study

30. COVID-19 infection in adult patients with hematological malignancies:a European Hematology Association Survey (EPICOVIDEHA)

31. Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with non‐Hodgkin lymphoma treated with B‐cell depleting immunotherapy

32. Malak, Sandra

33. Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older

34. Abstract S09-02: High incidence of persistent COVID-19 among patients with lymphoma treated with B-cell depleting immunotherapy

35. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

37. Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML

38. Characteristics and outcome of SARS-CoV-2 infection in cancer patients.

42. Bendamustine‐based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers

43. International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia

45. Bendamustine-EAM versusBEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers

47. Myelofibrosis in Real Life: Findings from the French Intergroup of Myeloproliferative Neoplasms (FIM) Registry

48. Clinical Efficacy of the Rivbd Combination for Refractory/Relapsed (R/R) Mantle Cell Lymphoma (MCL) Patients: A Retrospective Study of the French Lysa Group

50. Bendamustine-Based (BeEAM) Conditioning before Autologous Stem Cell Transplantation: Result of a French Multicenter Study of 386 Patients from Lysa Centers

Catalog

Books, media, physical & digital resources